Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
- Conditions
- Hematological Malignancies
- Interventions
- Biological: G-CSFRadiation: Total lymphoid irradiationBiological: Lymphocyte infusionsDevice: CliniMACS
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT02199041
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
- Conditions
- LeukemiaMDSLymphomaMyelofibrosis
- Interventions
- Radiation: Total Body IrradiationOther: Hematopoietic stem cell infusion
- First Posted Date
- 2014-06-19
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Rafic Farah, MD
- Target Recruit Count
- 28
- Registration Number
- NCT02167958
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT02106988
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
- Conditions
- Kidney Transplantation
- Interventions
- Biological: anti-thymocyte globulinRadiation: Total Body IrradiationBiological: bone marrow transplant
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2018-09-24
- Target Recruit Count
- 4
- Registration Number
- NCT02029638
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
- Conditions
- Germ Cell Tumors
- Interventions
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 92
- Registration Number
- NCT01873326
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
- Conditions
- Newly Diagnosed Ewing Sarcoma
- Interventions
- Device: DoxorubicinProcedure: SurgeryRadiation: Radiation Therapy*
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 83
- Registration Number
- NCT01864109
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Therapy for Children With Advanced Stage Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- Procedure: peripheral blood stem cell harvestProcedure: surgical resectionBiological: peripheral blood stem cell transplantationBiological: natural killer cell infusionRadiation: radiation therapyDevice: CliniMACS
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 153
- Registration Number
- NCT01857934
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Non-Myeloablative Conditioning and Bone Marrow Transplantation
- Conditions
- HemoglobinopathiesSickle Cell Disease
- Interventions
- Procedure: Bone marrow transplantationRadiation: Total body irradiation
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT01850108
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇫🇷Saint-Louis Hospital, Paris, France
🇬🇧St Mary's Hospital, London, United Kingdom
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
- Conditions
- LeukemiaLymphoma
- Interventions
- Radiation: Total Lymphoid IrradiationBiological: HPC,A InfusionBiological: TC-NK InfusionBiological: G-CSFDevice: CliniMACS
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT01807611
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
- Conditions
- Stage 2B NeuroblastomaStage 4S NeuroblastomaStage 1 NeuroblastomaStage 4 NeuroblastomaStage 2 NeuroblastomaGanglioneuroblastomaStage 2A NeuroblastomaStage 3 Neuroblastoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationRadiation: External Beam Radiation TherapyBiological: FilgrastimOther: Laboratory Biomarker AnalysisProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological Study
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 150
- Registration Number
- NCT01798004
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.